1. Home
  2. PMN vs HYFM Comparison

PMN vs HYFM Comparison

Compare PMN & HYFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$13.93

Market Cap

131.5M

Sector

Health Care

ML Signal

HOLD

Logo Hydrofarm Holdings Group Inc.

HYFM

Hydrofarm Holdings Group Inc.

HOLD

Current Price

$0.94

Market Cap

4.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMN
HYFM
Founded
2004
1977
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
131.5M
4.5M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
PMN
HYFM
Price
$13.93
$0.94
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$42.67
N/A
AVG Volume (30 Days)
36.1K
101.9K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$134,252,000.00
Revenue This Year
N/A
$57.44
Revenue Next Year
N/A
$5.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.50
52 Week High
$27.40
$3.69

Technical Indicators

Market Signals
Indicator
PMN
HYFM
Relative Strength Index (RSI) 53.41 46.70
Support Level $12.68 $0.94
Resistance Level $15.37 $1.08
Average True Range (ATR) 1.13 0.10
MACD 0.02 0.00
Stochastic Oscillator 68.15 53.47

Price Performance

Historical Comparison
PMN
HYFM

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is an independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (CEA), including grow lights, climate control solutions, grow media, nutrients, and other products. Hydroponics involves growing plants in soilless media, often using artificial lighting in controlled indoor or greenhouse environments. Its products are used to cultivate cannabis, flowers, fruits, vegetables, grains, and herbs, enabling control over key factors such as temperature, humidity, light, nutrients, and pH. Its product portfolio spans lighting, grow media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies. The United States generates maximum revenue.

Share on Social Networks: